<DOC>
	<DOC>NCT02487017</DOC>
	<brief_summary>Evaluation of DC-CIK cells combined TACE treatment for HCC</brief_summary>
	<brief_title>DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma</brief_title>
	<detailed_description>60 patients with Hepatocellular Carcinoma, who had received Transcatheter Arterial Chemoembolization (TACE) , will be randomly divided into group A (receive DC-CIK+ TACE treatment) or group B (just receive TACE), and the randomize ratio will be 1:1.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<criteria>1880 years old; Histologically confirmed with Hepatocellular Carcinoma at stage III; Patients who can accept Transcatheter Arterial Chemoembolization ; Patients who have a life expectancy of at least 3 months; Patients who have a ChildPugh:A/B; .Eastern Cooperative Oncology Group (ECOG) performance status was 02. White blood cell ＜3 x 10^9/L,Platelet count ＜75 x 10^9/L;BUN and Cr more than normal limits on 3.0 times ; Known or suspected allergy to the investigational agent or any agent given in association with this trial; Pregnant or lactating patients; Known history of Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) or TreponemaPallidun (TP) infection; Patients who are suffering from serious autoimmune disease; Patients who had used long time or are using immunosuppressant; Patients who had active infection; Prior use of any anticancer treatment in 30 days; Now or recently will join another experimental clinical study ; History of organ allograft; Other situations that the researchers considered unsuitable for this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>